HDAC inhibitors belonging to the hydroxamic acid class, in addition to breast cancer and lymphomas, are promising compounds for the treatment of melanoma [75], acute myeloid leukemia, leukemia, colorectal cancer, and gastric cancer. Here, HDAC9 is linked to lymphoma.